GeoVax Labs (GOVX) Projected to Post Earnings on Thursday

GeoVax Labs (NASDAQ:GOVX) is projected to announce its Q3 2026 resultson Thursday, November 12th. Analysts expect GeoVax Labs to announce earnings of ($1.09) per share for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 19, 2026 at 4:30 PM ET.

GeoVax Labs Stock Performance

GeoVax Labs stock opened at $0.14 on Tuesday. The firm’s fifty day moving average price is $0.32 and its 200-day moving average price is $1.19. The stock has a market cap of $1.05 million, a P/E ratio of -0.01 and a beta of 3.85. GeoVax Labs has a fifty-two week low of $0.14 and a fifty-two week high of $13.00.

Analyst Ratings Changes

Several brokerages recently issued reports on GOVX. Weiss Ratings reiterated a “sell (e+)” rating on shares of GeoVax Labs in a research report on Thursday, October 15th. Noble Financial restated an “outperform” rating on shares of GeoVax Labs in a research report on Tuesday, September 15th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, GeoVax Labs presently has an average rating of “Hold” and an average target price of $150.00.

GeoVax Labs Company Profile

GeoVax Labs, Inc is a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer. The company’s technology platform is based primarily on modified vaccinia Ankara (MVA) and virus-like particle (VLP) vaccine technologies, which are designed to generate broad and durable immune responses.

GeoVax’s pipeline has included GEO-CM04S1, a multivalent COVID-19 vaccine candidate intended to address emerging coronavirus variants, as well as investigational vaccines for HIV, hemorrhagic fever viruses such as Ebola and Marburg, and other infectious diseases.